Disparities in consent to adjuvant radiotherapy in primary glioblastoma: a population-based study.

IF 2.8 3区医学 Q2 ONCOLOGY Expert Review of Anticancer Therapy Pub Date : 2025-02-12 DOI:10.1080/14737140.2025.2464935

Wang Miao, Liu Yang, Jinhu Li, Xia Yan, Ying Lu, Xin Yang

{"title":"Disparities in consent to adjuvant radiotherapy in primary glioblastoma: a population-based study.","authors":"Wang Miao, Liu Yang, Jinhu Li, Xia Yan, Ying Lu, Xin Yang","doi":"10.1080/14737140.2025.2464935","DOIUrl":null,"url":null,"abstract":"Background: Despite adjuvant external beam radiation therapy (EBRT) has long been the standard treatment for glioblastoma (GBM), a significant subset of patients chooses to refuse it. We aimed to investigate the factors influencing EBRT refusal in GBM.Research design and methods: Patients with GBM were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Both univariable and multivariable logistic regression analyses were employed to evaluate the adjusted odds ratios (aOR) for the refusal of EBRT in relation to various clinical and demographic characteristics.Results: Among the 29,994 patients analyzed, 675 (2.3%) opted to refuse adjuvant EBRT. Patients aged ≥ 55 years (55-64: aOR 1.63, 95% CI 1.04-2.61, p = 0.03; 65-74: aOR 1.80, 95% CI 1.17-2.87, p = 0.009; 75+: aOR 2.01, 95% CI 1.28-3.24, p = 0.002), being single (aOR 1.68, 95% CI 1.19-2.35, p = 0.002), with a household income of $55,000 to $64,999 (aOR 1.94, 95% CI 1.24-3.07, p = 0.004), and not undergoing chemotherapy (aOR 114, 95% CI 80.2-170.2, p < 0.001) had significantly higher odds of refusing adjuvant EBRT.Conclusions: This study underscores the necessity for targeted communication strategies by physicians regarding the benefits of adjuvant EBRT.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-8"},"PeriodicalIF":2.8000,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2025.2464935","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Despite adjuvant external beam radiation therapy (EBRT) has long been the standard treatment for glioblastoma (GBM), a significant subset of patients chooses to refuse it. We aimed to investigate the factors influencing EBRT refusal in GBM.

Research design and methods: Patients with GBM were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Both univariable and multivariable logistic regression analyses were employed to evaluate the adjusted odds ratios (aOR) for the refusal of EBRT in relation to various clinical and demographic characteristics.

Results: Among the 29,994 patients analyzed, 675 (2.3%) opted to refuse adjuvant EBRT. Patients aged ≥ 55 years (55-64: aOR 1.63, 95% CI 1.04-2.61, p = 0.03; 65-74: aOR 1.80, 95% CI 1.17-2.87, p = 0.009; 75+: aOR 2.01, 95% CI 1.28-3.24, p = 0.002), being single (aOR 1.68, 95% CI 1.19-2.35, p = 0.002), with a household income of $55,000 to $64,999 (aOR 1.94, 95% CI 1.24-3.07, p = 0.004), and not undergoing chemotherapy (aOR 114, 95% CI 80.2-170.2, p < 0.001) had significantly higher odds of refusing adjuvant EBRT.

Conclusions: This study underscores the necessity for targeted communication strategies by physicians regarding the benefits of adjuvant EBRT.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

原发性胶质母细胞瘤患者对辅助放疗的同意差异：一项基于人群的研究。

背景：尽管辅助外束放射治疗（EBRT）长期以来一直是胶质母细胞瘤（GBM）的标准治疗方法，但仍有相当一部分患者选择拒绝接受。我们的目的是探讨影响GBM患者EBRT拒绝的因素。研究设计和方法：从监测、流行病学和最终结果（SEER）数据库中确定GBM患者。采用单变量和多变量logistic回归分析来评估拒绝EBRT的调整优势比（aOR）与各种临床和人口统计学特征的关系。结果：在分析的29,994例患者中，675例（2.3%）选择拒绝辅助EBRT。年龄≥55岁患者(55 ~ 64岁：aOR 1.63, 95% CI 1.04 ~ 2.61, p = 0.03；65 ~ 74: aOR 1.80, 95% CI 1.17 ~ 2.87, p = 0.009；75+: aOR 2.01, 95% CI 1.28-3.24, p = 0.002)，单身（aOR 1.68, 95% CI 1.19-2.35, p = 0.002），家庭收入在55,000至64,999美元（aOR 1.94, 95% CI 1.24-3.07, p = 0.004），未接受化疗（aOR 114, 95% CI 80.2-170.2, p）。结论：本研究强调了医生有必要针对辅助EBRT的益处进行有针对性的沟通策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Expert Review of Anticancer Therapy 医学-肿瘤学

CiteScore

5.10

自引率

3.00%

发文量

100

审稿时长

4-8 weeks

期刊介绍： Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches. Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care. Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.